European Heart Journal-Cardiovascular Pharmacotherapy

Article	Citations
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	97
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	74
Early initiation of SGLT2 inhibitors after acute myocardial infarction	69
Finerenone for Diabetic Hearts: A Critical Appraisal of MACE Benefits and the Research Road Ahead	60
The role of aetiology in determining anticoagulation effectiveness for the treatment of left ventricular thrombus	59
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	48
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	45
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	45
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	42
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?	39
Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study	37
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	35
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	34
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	34
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	33
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	32
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	29
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	29
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	29
All about clinical trials	26
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy	25
New ways of mitigating aldosterone in cardiorenal disease	25
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data	25
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	25
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease	25

Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on 1-year mortality in acute coronary syndrome patients	23
Authors’ reply to: ‘preventing atrial fibrillation with SGLT2 inhibitors: time, sex, and substrate’ by Karakasis et al .	23
SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data	23
Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy	23
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	23
De-escalation versus shortening of dual antiplatelet therapy	22
Long-term antiplatelet monotherapy after PCI: searching for the smart choice	22
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease	21
OCEAN trial: rethinking long-term anticoagulation after atrial fibrillation ablation	21
Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention	20
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis	20
News in cardiovascular pharmacotherapy from the ACC.24 Meeting	19
SGLT2 Inhibitors in Heart Failure With Tricuspid Regurgitation: Clinical Interpretation and Future Directions	19
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-	19
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic	19
Cardiovascular prevention and risk factors	19
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results	18
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts	18
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial	18
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials	18
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023	17
Reply to ‘Sacubitril/valsartan in heart failure: a critical look at dementia risk and future study pathways’	17
Entering a new era of antiplatelet therapy: the 4D-ACS trial	17
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies	17
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry	16
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis	16
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!	16
Focus on different aspects of atrial fibrillation	15
A farewell to professor Stefan Agewall from the ESC Working Group on Cardiovascular Pharmacotherapy	15
Are NOACs always the best strategy in elderly AF patients?	15
Correction to: Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	15
What's new in pharmacotherapy at ESC Congress 2023?	14
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study	14
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes	14
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry	14
Initiation of Eplerenone vs Spironolactone and All-cause Mortality in HFrEF: Linked Database Study	14
Seeking for the boundaries of de-escalation in antiplatelet therapy for acute coronary syndrome	14
Different aspects of pharmacological heart failure treatment	13
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr	13
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?	13
Impact of single vs. dual local anaesthetic regimen on the efficacy and safety of percutaneous stellate ganglion block for electrical storm: new insights from the STAR study	13
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022	13
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?	13
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation	13
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis	13
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis	13
An old drug in a new era: digitoxin in the spotlight after DIGIT-HF	12
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials	12
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue	12
Cardiotoxicity in dual immune checkpoint inhibitors: a critical appraisal of signal interpretation and future directions	12

New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study	12
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials	12
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study	11
RNA-targeted therapeutics in cardiovascular disease: the time is now	11
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark	11
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study	11
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm	11
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease	11
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry	11
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding	10
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study	10
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial	10
FLOW trial stopped early due to evidence of renal protection with semaglutide	10
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure	10
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial	10
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation	10
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists	10
Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials	10
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies	9
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF	9
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study	9
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study	9
News in cardiovascular pharmacotherapy from the ACC.25 Meeting	9
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease	8
The role of inotropes in cardiogenic shock: to help, to harm or do nothing at all?	8
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial	8
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT	8
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy?	8
Future of antithrombotic therapy for heart failure with coronary artery disease	8
Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug	8
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?	8
Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis	8
Special focus on the new anti-diabetic drugs	8
Antiplatelet treatment, dyslipidemia, cardiac side events during COVID-19 vaccine, antithrombotic treatment with different BMI	7
Management of dyslipidaemia in patients with comorbidities: facing the challenge	7
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure	7
Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that?	7
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate	7
Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function—a prespecified substudy from REDUCE-AMI	7
Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results	7
Lipid treatment	7
Different aspects of myocardial intervention and pharmacological treatment	7
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance	7
Combination therapy with moderate-intensity atorvastatin and ezetimibe vs. high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RA	7
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation	7
Correction to: New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	7
Early DAPT discontinuation after acute myocardial infarction: finding the optimal TARGET	7
LDL lowering effect of PCSK9 inhibition is reduced in women	7
Our knowledge about atrial fibrillation steadily increases	6
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study	6
Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography—a subanalysis of the EMPAG-HF trial	6
EHJCVP Reviewers 2022	6
Pharmacogenetic testing to broaden patient eligibility for mavacamten	6
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome	6
Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry	6
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?	6
Mechanistic Insights into SGLT2 Inhibition in Takotsubo Syndrome	6
The impact of sodium–glucose cotransporter 2 inhibitors in post-myocardial infarction management: insights from EMPACT-MI and DAPA-MI trials	6
The search for the perfect antiplatelet treatment continues	6
SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis	6
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease	6
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics	6
Corrigendum to: The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	6
Letter to the editor: 1-year clinical outcomes of bivalirudin vs. unfractionated heparin in patients with type 2 diabetes undergoing elective percutaneous coronary intervention	6
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity	6
The role of cangrelor in acute and high-risk PCI settings	6
Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study	5
Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study	5
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction	5
Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinic	5
Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure	5
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry	5
End of the first decade of EHJ CVP	5
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis	5
CLEAR results, cloudy impact: colchicine's neutral role in ST-segment elevation myocardial infarction	5
Antithrombotic therapy in patients after transcatheter aortic valve implantation: a network meta-analysis	5
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials	5
Beta-adrenergic blockade increases pulmonary vascular resistance and causes exaggerated hypoxic pulmonary vasoconstriction at high altitude: a physiological study	5
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?	5
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis	5

Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition	5
2022 ESC Guidelines on cardio-oncology: how can we improve the cardiovascular health of patients with cancer and cancer survivors?	5
Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study	5
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	5
Bleeding and thrombosis	4
Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data	4
Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus	4
The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide co	4
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial	4
Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study	4
Post-operative atrial fibrillation and stroke after non-cardiac surgery: a systematic review and meta-analysis	4
Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational	4
Why does research integrity affect us all?	4
Reply to ‘Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction’	4
Post-diagnostic statin use and its association with cancer recurrence and mortality in breast cancer patients: a systematic review and meta-analysis	4
ODYSSEY-HCM trial (mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy)	4
Hypertension in pregnancy—what's new in the 2023 ESH Guidelines for the management of arterial hypertension	4
What is optimal dual anti-platelet therapy duration after percutaneous coronary intervention?	4
Sex-related differences in platelet aggregation	4
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy	4
Reaping the rewards of a simplified dosing regimen	4
GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease	4
Antidiabetic drugs and hypoglycaemia risk in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants	4
Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases	3
First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA	3
Correction to: Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials	3
Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation	3
Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials	3
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics	3
Balancing the risks of bleeding and ischaemia in myocardial infarction patients at high bleeding risk	3
Subcutaneous furosemide in heart failure: a systematic review	3
Beta-blockers after myocardial infarction: time to change the guidelines	3
After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension	3
Long-term effectiveness of ACE inhibitors or angiotensin receptor blockers in myocardial infarction with preserved left ventricular ejection fraction	3
Anticoagulation in cancer-associated thrombosis: how long should the therapy be?	3
Oral anticoagulants and antiplatelet treatment in different settings	3
Fibrates: one more lost paradise in lipid treatment	3
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock	3
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events	3
VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention	3
Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes	3
Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis	3
Reduction of hypokalaemia with finerenone: a drug or class-specific effect?	3